Brian Shuch, MD, of UCLA Health, previews his upcoming sessions at Urology on the Beach 2025, taking place January 17, 2025, to January 19, 2025, at the Fontainebleau Miami Beach. This comprehensive event covers all aspects of urology with presentations from leading experts in the field. Dr. Shuch’s presentation will cover the use of molecular imaging agents and their role in risk stratification and informed treatment decisions. ...
Renal Cell Carcinoma
Advertisement
Latest News
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Higher PSMA expression in non-metastatic ccRCC correlates with improved progression-free survival, study shows.
Patient-derived organoids show promise in RCC, enabling personalized therapies and resistance insights.
New data shows patients with nccRCC may benefit from adjuvant therapy at a comparable rate as patients with ccRCC.
Dr. Barragán-Carrillo discusses the current state of RCC treatment, including ICIs, TKIs, and dual ICI regimens.
For the study, researchers identified potential protein biomarkers for diagnosing and prognosticating renal cell carcinoma.
Advertisement
Knowledge Hub Spotlights
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
Advertisement
Advertisement
Latest News
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.